ID   PLCG1_HUMAN             Reviewed;        1290 AA.
AC   P19174; B7ZLY7; B9EGH4; E1P5W4; Q2V575;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   10-MAY-2017, entry version 216.
DE   RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1;
DE            EC=3.1.4.11;
DE   AltName: Full=PLC-148;
DE   AltName: Full=Phosphoinositide phospholipase C-gamma-1;
DE   AltName: Full=Phospholipase C-II;
DE            Short=PLC-II;
DE   AltName: Full=Phospholipase C-gamma-1;
DE            Short=PLC-gamma-1;
GN   Name=PLCG1; Synonyms=PLC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PHOSPHORYLATION.
RC   TISSUE=Brain, and Vein;
RX   PubMed=2167438; DOI=10.1128/MCB.10.9.4770;
RA   Burgess W.H., Dionne C.A., Kaplow J.M., Mudd R., Friesel R.,
RA   Zilberstein A., Schlessinger J., Jaye M.;
RT   "Characterization and cDNA cloning of phospholipase C-gamma, a major
RT   substrate for heparin-binding growth factor 1 (acidic fibroblast
RT   growth factor)-activated tyrosine kinase.";
RL   Mol. Cell. Biol. 10:4770-4777(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ASN-209; GLY-279;
RP   THR-739 AND THR-813.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   THR-813.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH FGFR1.
RX   PubMed=1656221; DOI=10.1128/MCB.11.10.5068;
RA   Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W.,
RA   Dionne C.A., Jaye M., Rubinstein M., Schlessinger J.;
RT   "A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast
RT   growth factor receptor (Flg) is a binding site for the SH2 domain of
RT   phospholipase C-gamma 1.";
RL   Mol. Cell. Biol. 11:5068-5078(1991).
RN   [7]
RP   PHOSPHORYLATION AT SER-1248.
RX   PubMed=1370476;
RA   Park D.J., Min H.K., Rhee S.G.;
RT   "Inhibition of CD3-linked phospholipase C by phorbol ester and by cAMP
RT   is associated with decreased phosphotyrosine and increased
RT   phosphoserine contents of PLC-gamma 1.";
RL   J. Biol. Chem. 267:1496-1501(1992).
RN   [8]
RP   INTERACTION WITH FGFR4.
RX   PubMed=7518429;
RA   Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G.,
RA   Alitalo K.;
RT   "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4).
RT   Comparison with FGFR-1.";
RL   J. Biol. Chem. 269:18320-18326(1994).
RN   [9]
RP   PHOSPHORYLATION AT TYR-771 AND TYR-783 BY SYK, AND INTERACTION WITH
RP   SYK.
RX   PubMed=8657103; DOI=10.1128/MCB.16.4.1305;
RA   Law C.L., Chandran K.A., Sidorenko S.P., Clark E.A.;
RT   "Phospholipase C-gamma1 interacts with conserved phosphotyrosyl
RT   residues in the linker region of Syk and is a substrate for Syk.";
RL   Mol. Cell. Biol. 16:1305-1315(1996).
RN   [10]
RP   INTERACTION WITH KIT.
RX   PubMed=9038210; DOI=10.1074/jbc.272.9.5915;
RA   Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.;
RT   "Direct association of Csk homologous kinase (CHK) with the
RT   diphosphorylated site Tyr568/570 of the activated c-KIT in
RT   megakaryocytes.";
RL   J. Biol. Chem. 272:5915-5920(1997).
RN   [11]
RP   INTERACTION WITH AXL.
RX   PubMed=9178760; DOI=10.1038/sj.onc.1201123;
RA   Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R.,
RA   Ullrich A., Bartram C.R., Janssen J.W.;
RT   "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is
RT   mediated mainly by a multi-substrate docking-site.";
RL   Oncogene 14:2619-2631(1997).
RN   [12]
RP   INTERACTION WITH LAT.
RX   PubMed=9489702; DOI=10.1016/S0092-8674(00)80901-0;
RA   Zhang W., Sloan-Lancaster J., Kitchen J., Trible R.P., Samelson L.E.;
RT   "LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor
RT   to cellular activation.";
RL   Cell 92:83-92(1998).
RN   [13]
RP   INTERACTION WITH SHB.
RX   PubMed=10488157; DOI=10.1074/jbc.274.39.28050;
RA   Lindholm C.K., Gylfe E., Zhang W., Samelson L.E., Welsh M.;
RT   "Requirement of the Src homology 2 domain protein Shb for T cell
RT   receptor-dependent activation of the interleukin-2 gene nuclear factor
RT   for activation of T cells element in Jurkat T cells.";
RL   J. Biol. Chem. 274:28050-28057(1999).
RN   [14]
RP   PHOSPHORYLATION BY KDR.
RX   PubMed=10102632; DOI=10.1038/sj.onc.1202478;
RA   Dougher M., Terman B.I.;
RT   "Autophosphorylation of KDR in the kinase domain is required for
RT   maximal VEGF-stimulated kinase activity and receptor
RT   internalization.";
RL   Oncogene 18:1619-1627(1999).
RN   [15]
RP   INTERACTION WITH TNK1.
RX   PubMed=10873601; DOI=10.1006/bbrc.2000.2887;
RA   Felschow D.M., Civin C.I., Hoehn G.T.;
RT   "Characterization of the tyrosine kinase Tnk1 and its binding with
RT   phospholipase C-gamma1.";
RL   Biochem. Biophys. Res. Commun. 273:294-301(2000).
RN   [16]
RP   INTERACTION WITH HEV ORF3 PROTEIN.
RX   PubMed=11518702; DOI=10.1074/jbc.M101546200;
RA   Korkaya H., Jameel S., Gupta D., Tyagi S., Kumar R., Zafrullah M.,
RA   Mazumdar M., Lal S.K., Xiaofang L., Sehgal D., Das S.R., Sahal D.;
RT   "The ORF3 protein of hepatitis E virus binds to Src homology 3 domains
RT   and activates MAPK.";
RL   J. Biol. Chem. 276:42389-42400(2001).
RN   [17]
RP   INTERACTION WITH RALGPS1.
RX   PubMed=10747847; DOI=10.1074/jbc.C000085200;
RA   Rebhun J.F., Chen H., Quilliam L.A.;
RT   "Identification and characterization of a new family of guanine
RT   nucleotide exchange factors for the ras-related GTPase Ral.";
RL   J. Biol. Chem. 275:13406-13410(2000).
RN   [18]
RP   PROBABLE DEPHOSPHORYLATION BY PTPRJ.
RX   PubMed=11259588; DOI=10.1128/MCB.21.7.2393-2403.2001;
RA   Baker J.E., Majeti R., Tangye S.G., Weiss A.;
RT   "Protein tyrosine phosphatase CD148-mediated inhibition of T-cell
RT   receptor signal transduction is associated with reduced LAT and
RT   phospholipase Cgamma1 phosphorylation.";
RL   Mol. Cell. Biol. 21:2393-2403(2001).
RN   [19]
RP   PHOSPHORYLATION AT TYR-783, AND SUBCELLULAR LOCATION.
RX   PubMed=11564877; DOI=10.1128/MCB.21.20.6939-6950.2001;
RA   Veri M.C., DeBell K.E., Seminario M.C., DiBaldassarre A., Reischl I.,
RA   Rawat R., Graham L., Noviello C., Rellahan B.L., Miscia S.,
RA   Wange R.L., Bonvini E.;
RT   "Membrane raft-dependent regulation of phospholipase Cgamma-1
RT   activation in T lymphocytes.";
RL   Mol. Cell. Biol. 21:6939-6950(2001).
RN   [20]
RP   PROBABLE DEPHOSPHORYLATION BY PTPRJ.
RX   PubMed=12913111; DOI=10.1083/jcb.200303040;
RA   Lin J., Weiss A.;
RT   "The tyrosine phosphatase CD148 is excluded from the immunologic
RT   synapse and down-regulates prolonged T cell signaling.";
RL   J. Cell Biol. 162:673-682(2003).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-771 AND TYR-1253, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [22]
RP   INTERACTION WITH NTRK1.
RX   PubMed=15488758; DOI=10.1016/j.ccr.2004.09.011;
RA   Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A.,
RA   Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A.,
RA   Mackay A.R.;
RT   "TrkA alternative splicing: a regulated tumor-promoting switch in
RT   human neuroblastoma.";
RL   Cancer Cell 6:347-360(2004).
RN   [23]
RP   REVIEW ON INTERACTION WITH KIT AND ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [24]
RP   INTERACTION WITH BLNK; VAV1; GRB2 AND NCK1.
RX   PubMed=15270728; DOI=10.1111/j.1365-2567.2004.01918.x;
RA   Taguchi T., Kiyokawa N., Takenouch H., Matsui J., Tang W.-R.,
RA   Nakajima H., Suzuki K., Shiozawa Y., Saito M., Katagiri Y.U.,
RA   Takahashi T., Karasuyama H., Matsuo Y., Okita H., Fujimoto J.;
RT   "Deficiency of BLNK hampers PLC-gamma2 phosphorylation and Ca2+ influx
RT   induced by the pre-B-cell receptor in human pre-B cells.";
RL   Immunology 112:575-582(2004).
RN   [25]
RP   INTERACTION WITH FLT4.
RX   PubMed=15102829; DOI=10.1074/jbc.M314015200;
RA   Wang J.F., Zhang X., Groopman J.E.;
RT   "Activation of vascular endothelial growth factor receptor-3 and its
RT   downstream signaling promote cell survival under oxidative stress.";
RL   J. Biol. Chem. 279:27088-27097(2004).
RN   [26]
RP   PHOSPHORYLATION AT TYR-783 IN RESPONSE TO KDR ACTIVATION.
RX   PubMed=15215251; DOI=10.1074/jbc.M401538200;
RA   Jia H., Bagherzadeh A., Bicknell R., Duchen M.R., Liu D., Zachary I.;
RT   "Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially
RT   regulate KDR-mediated signaling and biological function in vascular
RT   endothelial cells.";
RL   J. Biol. Chem. 279:36148-36157(2004).
RN   [27]
RP   PHOSPHORYLATION BY ITK.
RX   PubMed=16081816; DOI=10.4049/jimmunol.175.4.2449;
RA   Houtman J.C., Houghtling R.A., Barda-Saad M., Toda Y., Samelson L.E.;
RT   "Early phosphorylation kinetics of proteins involved in proximal TCR-
RT   mediated signaling pathways.";
RL   J. Immunol. 175:2449-2458(2005).
RN   [28]
RP   INTERACTION WITH FGFR2, AND PHOSPHORYLATION.
RX   PubMed=16844695; DOI=10.1074/jbc.M600448200;
RA   Hatch N.E., Hudson M., Seto M.L., Cunningham M.L., Bothwell M.;
RT   "Intracellular retention, degradation, and signaling of glycosylation-
RT   deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.";
RL   J. Biol. Chem. 281:27292-27305(2006).
RN   [29]
RP   FUNCTION, INTERACTION WITH VIL1, AND SUBCELLULAR LOCATION.
RX   PubMed=17229814; DOI=10.1152/ajpcell.00420.2006;
RA   Wang Y., Tomar A., George S.P., Khurana S.;
RT   "Obligatory role for phospholipase C-gamma(1) in villin-induced
RT   epithelial cell migration.";
RL   Am. J. Physiol. 292:C1775-C1786(2007).
RN   [30]
RP   PHOSPHORYLATION BY FGFR3.
RX   PubMed=17561467; DOI=10.1016/j.bone.2006.11.030;
RA   Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y.,
RA   Tanaka H.;
RT   "Sustained phosphorylation of mutated FGFR3 is a crucial feature of
RT   genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell
RT   line via PLCgamma-activated STAT1.";
RL   Bone 41:273-281(2007).
RN   [31]
RP   INTERACTION WITH PDGFRB.
RX   PubMed=17620338; DOI=10.1074/jbc.M701797200;
RA   Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P.,
RA   Druker B.J., Naramura M., Band V., Band H.;
RT   "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-
RT   derived growth factor receptor beta provides a dual mechanism of
RT   negative regulation.";
RL   J. Biol. Chem. 282:29336-29347(2007).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1221, PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT SER-1222 (ISOFORM 2), AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [33]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [34]
RP   INTERACTION WITH FGFR3.
RX   PubMed=19286672; DOI=10.1093/hmg/ddp116;
RA   Salazar L., Kashiwada T., Krejci P., Muchowski P., Donoghue D.,
RA   Wilcox W.R., Thompson L.M.;
RT   "A novel interaction between fibroblast growth factor receptor 3 and
RT   the p85 subunit of phosphoinositide 3-kinase: activation-dependent
RT   regulation of ERK by p85 in multiple myeloma cells.";
RL   Hum. Mol. Genet. 18:1951-1961(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-771; TYR-775; TYR-783
RP   AND SER-1221, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1222
RP   (ISOFORM 2), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [36]
RP   INTERACTION WITH PDGFRB, AND PHOSPHORYLATION AT TYR-771.
RX   PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004;
RA   Wardega P., Heldin C.H., Lennartsson J.;
RT   "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects
RT   cell proliferation but not migration.";
RL   Cell. Signal. 22:1363-1368(2010).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1221 AND TYR-1253, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [39]
RP   INTERACTION WITH FGFR1, AND PHOSPHORYLATION BY FGFR1.
RX   PubMed=21765395; DOI=10.1038/emboj.2011.234;
RA   Persaud A., Alberts P., Hayes M., Guettler S., Clarke I., Sicheri F.,
RA   Dirks P., Ciruna B., Rotin D.;
RT   "Nedd4-1 binds and ubiquitylates activated FGFR1 to control its
RT   endocytosis and function.";
RL   EMBO J. 30:3259-3273(2011).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1222 (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [41]
RP   INTERACTION WITH TESPA1.
RC   TISSUE=Thymocyte;
RX   PubMed=22561606; DOI=10.1038/ni.2301;
RA   Wang D., Zheng M., Lei L., Ji J., Yao Y., Qiu Y., Ma L., Lou J.,
RA   Ouyang C., Zhang X., He Y., Chi J., Wang L., Kuang Y., Wang J.,
RA   Cao X., Lu L.;
RT   "Tespa1 is involved in late thymocyte development through the
RT   regulation of TCR-mediated signaling.";
RL   Nat. Immunol. 13:560-568(2012).
RN   [42]
RP   REVIEW ON ROLE IN FGF-ACTIVATED SIGNALING PATHWAYS.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1221; SER-1227; SER-1233
RP   AND SER-1263, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [44]
RP   STRUCTURE BY NMR OF SH3 DOMAIN.
RX   PubMed=7681365; DOI=10.1016/0092-8674(93)90583-C;
RA   Kohda D., Hatanaka H., Odaka M., Mandiyan V., Ullrich A.,
RA   Schlessinger J., Inagaki F.;
RT   "Solution structure of the SH3 domain of phospholipase C-gamma.";
RL   Cell 72:953-960(1993).
CC   -!- FUNCTION: Mediates the production of the second messenger
CC       molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate
CC       (IP3). Plays an important role in the regulation of intracellular
CC       signaling cascades. Becomes activated in response to ligand-
CC       mediated activation of receptor-type tyrosine kinases, such as
CC       PDGFRA, PDGFRB, FGFR1, FGFR2, FGFR3 and FGFR4. Plays a role in
CC       actin reorganization and cell migration.
CC       {ECO:0000269|PubMed:17229814}.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate + H(2)O = 1D-myo-inositol 1,4,5-trisphosphate +
CC       diacylglycerol.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC   -!- ENZYME REGULATION: Activated by phosphorylation on tyrosine
CC       residues.
CC   -!- SUBUNIT: Interacts with AGAP2 via its SH3 domain. Interacts (via
CC       SH2 domain) with RET. Interacts with FLT1 (tyrosine-
CC       phosphorylated) (By similarity). Interacts (via SH2 domain) with
CC       FGFR1, FGFR2, FGFR3 and FGFR4 (phosphorylated). Interacts with LAT
CC       (phosphorylated) upon TCR activation. Interacts (via SH3 domain)
CC       with the Pro-rich domain of TNK1. Associates with BLNK, VAV1, GRB2
CC       and NCK1 in a B-cell antigen receptor-dependent fashion. Interacts
CC       with CBLB in activated T-cells; which inhibits phosphorylation.
CC       Interacts with SHB. Interacts (via SH3 domain) with the Arg/Gly-
CC       rich-flanked Pro-rich domains of KHDRBS1/SAM68. This interaction
CC       is selectively regulated by arginine methylation of KHDRBS1/SAM68.
CC       Interacts with INPP5D/SHIP1, THEMIS and CLNK (By similarity).
CC       Interacts with AXL, FLT4 and KIT. Interacts with RALGPS1.
CC       Interacts (via SH3 domain) with HEV ORF3 protein. Interacts (via
CC       the SH2 domains) with VIL1 (phosphorylated at C-terminus tyrosine
CC       phosphorylation sites). Interacts (via SH2 domain) with PDGFRA and
CC       PDGFRB (tyrosine phosphorylated). Interacts with PIP5K1C (By
CC       similarity). Interacts with NTRK1 and NTRK2 (phosphorylated upon
CC       ligand-binding). Interacts with SYK; activates PLCG1. Interacts
CC       with GRB2, LAT and THEMIS upon TCR activation in thymocytes (By
CC       similarity). Interacts with TESPA1; the association is increased
CC       with prolonged stimulation of the TCR and may facilitate the
CC       assembly of the LAT signalosome. {ECO:0000250,
CC       ECO:0000269|PubMed:10488157, ECO:0000269|PubMed:10747847,
CC       ECO:0000269|PubMed:10873601, ECO:0000269|PubMed:11518702,
CC       ECO:0000269|PubMed:15102829, ECO:0000269|PubMed:15270728,
CC       ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:1656221,
CC       ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17229814,
CC       ECO:0000269|PubMed:17620338, ECO:0000269|PubMed:19286672,
CC       ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:21765395,
CC       ECO:0000269|PubMed:22561606, ECO:0000269|PubMed:7518429,
CC       ECO:0000269|PubMed:8657103, ECO:0000269|PubMed:9038210,
CC       ECO:0000269|PubMed:9178760, ECO:0000269|PubMed:9489702}.
CC   -!- INTERACTION:
CC       P42684:ABL2; NbExp=4; IntAct=EBI-79387, EBI-1102694;
CC       P31749:AKT1; NbExp=9; IntAct=EBI-79387, EBI-296087;
CC       P10275:AR; NbExp=22; IntAct=EBI-79387, EBI-608057;
CC       Q9ULH1:ASAP1; NbExp=3; IntAct=EBI-79387, EBI-346622;
CC       O43150:ASAP2; NbExp=3; IntAct=EBI-79387, EBI-310968;
CC       P20273:CD22; NbExp=2; IntAct=EBI-79387, EBI-78277;
CC       Q9BZW8:CD244; NbExp=2; IntAct=EBI-79387, EBI-1580565;
CC       Q9H1R2:DUSP15; NbExp=2; IntAct=EBI-79387, EBI-1752795;
CC       Q71V39:EEF1A2 (xeno); NbExp=3; IntAct=EBI-79387, EBI-7645815;
CC       P00533:EGFR; NbExp=6; IntAct=EBI-79387, EBI-297353;
CC       P04626:ERBB2; NbExp=5; IntAct=EBI-79387, EBI-641062;
CC       P21860:ERBB3; NbExp=4; IntAct=EBI-79387, EBI-720706;
CC       P31994:FCGR2B; NbExp=2; IntAct=EBI-79387, EBI-724784;
CC       P11362:FGFR1; NbExp=5; IntAct=EBI-79387, EBI-1028277;
CC       P17948:FLT1; NbExp=2; IntAct=EBI-79387, EBI-1026718;
CC       Q13480:GAB1; NbExp=36; IntAct=EBI-79387, EBI-517684;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-79387, EBI-401755;
CC       P08631:HCK; NbExp=2; IntAct=EBI-79387, EBI-346340;
CC       P06213:INSR; NbExp=9; IntAct=EBI-79387, EBI-475899;
CC       Q07666:KHDRBS1; NbExp=2; IntAct=EBI-79387, EBI-1364;
CC       P10721:KIT; NbExp=31; IntAct=EBI-79387, EBI-1379503;
CC       O43561:LAT; NbExp=7; IntAct=EBI-79387, EBI-1222766;
CC       Q13094:LCP2; NbExp=3; IntAct=EBI-79387, EBI-346946;
CC       Q92918:MAP4K1; NbExp=6; IntAct=EBI-79387, EBI-881;
CC       P08581:MET; NbExp=10; IntAct=EBI-79387, EBI-1039152;
CC       P09619:PDGFRB; NbExp=5; IntAct=EBI-79387, EBI-641237;
CC       P63000:RAC1; NbExp=7; IntAct=EBI-79387, EBI-413628;
CC       P07949:RET; NbExp=2; IntAct=EBI-79387, EBI-2480756;
CC       Q8TB24:RIN3; NbExp=3; IntAct=EBI-79387, EBI-1570523;
CC       Q14108:SCARB2; NbExp=2; IntAct=EBI-79387, EBI-1564650;
CC       O14796:SH2D1B; NbExp=2; IntAct=EBI-79387, EBI-3923013;
CC       Q9UPX8:SHANK2; NbExp=4; IntAct=EBI-79387, EBI-1570571;
CC       Q9BYB0:SHANK3; NbExp=2; IntAct=EBI-79387, EBI-1752330;
CC       Q15036:SNX17; NbExp=2; IntAct=EBI-79387, EBI-1752620;
CC       Q07889:SOS1; NbExp=3; IntAct=EBI-79387, EBI-297487;
CC       Q07890:SOS2; NbExp=4; IntAct=EBI-79387, EBI-298181;
CC       P43405:SYK; NbExp=4; IntAct=EBI-79387, EBI-78302;
CC       P09327:VIL1; NbExp=5; IntAct=EBI-79387, EBI-746958;
CC   -!- SUBCELLULAR LOCATION: Cell projection, lamellipodium. Cell
CC       projection, ruffle. Note=Rapidly redistributed to ruffles and
CC       lamellipodia structures in response to epidermal growth factor
CC       (EGF) treatment.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P19174-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19174-2; Sequence=VSP_038692;
CC         Note=Contains a phosphoserine at position 1222.
CC         {ECO:0000244|PubMed:18669648, ECO:0000244|PubMed:19690332,
CC         ECO:0000244|PubMed:21406692};
CC   -!- DOMAIN: The SH3 domain mediates interaction with CLNK (By
CC       similarity). The SH3 domain also mediates interaction with
CC       RALGPS1. {ECO:0000250}.
CC   -!- PTM: Tyrosine phosphorylated in response to signaling via
CC       activated FLT3, KIT and PDGFRA (By similarity). Tyrosine
CC       phosphorylated by activated FGFR1, FGFR2, FGFR3 and FGFR4.
CC       Tyrosine phosphorylated by activated FLT1 and KDR. Tyrosine
CC       phosphorylated by activated PDGFRB. The receptor-mediated
CC       activation of PLCG1 involves its phosphorylation by tyrosine
CC       kinases, in response to ligation of a variety of growth factor
CC       receptors and immune system receptors. For instance, SYK
CC       phosphorylates and activates PLCG1 in response to ligation of the
CC       B-cell receptor. May be dephosphorylated by PTPRJ. Phosphorylated
CC       by ITK and TXK on Tyr-783 upon TCR activation in T-cells.
CC       {ECO:0000250, ECO:0000269|PubMed:10102632,
CC       ECO:0000269|PubMed:11564877, ECO:0000269|PubMed:1370476,
CC       ECO:0000269|PubMed:15215251, ECO:0000269|PubMed:16081816,
CC       ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:17561467,
CC       ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:2167438,
CC       ECO:0000269|PubMed:21765395, ECO:0000269|PubMed:8657103}.
CC   -!- PTM: Ubiquitinated by CBLB in activated T-cells. {ECO:0000250}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/plcg1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M34667; AAA36452.1; -; mRNA.
DR   EMBL; DQ297143; ABB84466.1; -; Genomic_DNA.
DR   EMBL; AL022394; CAA18537.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75991.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75992.1; -; Genomic_DNA.
DR   EMBL; BC136466; AAI36467.1; -; mRNA.
DR   EMBL; BC144136; AAI44137.1; -; mRNA.
DR   CCDS; CCDS13313.1; -. [P19174-2]
DR   CCDS; CCDS13314.1; -. [P19174-1]
DR   PIR; A36466; A36466.
DR   RefSeq; NP_002651.2; NM_002660.2. [P19174-2]
DR   RefSeq; NP_877963.1; NM_182811.1. [P19174-1]
DR   UniGene; Hs.268177; -.
DR   PDB; 1HSQ; NMR; -; A=790-851.
DR   PDB; 2HSP; NMR; -; A=790-851.
DR   PDB; 4EY0; X-ray; 2.80 A; A/B/C/D=545-790.
DR   PDB; 4FBN; X-ray; 2.40 A; A=545-790.
DR   PDBsum; 1HSQ; -.
DR   PDBsum; 2HSP; -.
DR   PDBsum; 4EY0; -.
DR   PDBsum; 4FBN; -.
DR   ProteinModelPortal; P19174; -.
DR   SMR; P19174; -.
DR   BioGrid; 111351; 123.
DR   DIP; DIP-100N; -.
DR   IntAct; P19174; 113.
DR   MINT; MINT-102915; -.
DR   STRING; 9606.ENSP00000244007; -.
DR   BindingDB; P19174; -.
DR   ChEMBL; CHEMBL3964; -.
DR   iPTMnet; P19174; -.
DR   PhosphoSitePlus; P19174; -.
DR   BioMuta; PLCG1; -.
DR   DMDM; 130225; -.
DR   EPD; P19174; -.
DR   MaxQB; P19174; -.
DR   PaxDb; P19174; -.
DR   PeptideAtlas; P19174; -.
DR   PRIDE; P19174; -.
DR   DNASU; 5335; -.
DR   Ensembl; ENST00000244007; ENSP00000244007; ENSG00000124181. [P19174-2]
DR   Ensembl; ENST00000373271; ENSP00000362368; ENSG00000124181. [P19174-1]
DR   GeneID; 5335; -.
DR   KEGG; hsa:5335; -.
DR   UCSC; uc002xjo.2; human. [P19174-1]
DR   CTD; 5335; -.
DR   DisGeNET; 5335; -.
DR   GeneCards; PLCG1; -.
DR   HGNC; HGNC:9065; PLCG1.
DR   HPA; CAB004277; -.
DR   HPA; HPA036681; -.
DR   HPA; HPA036682; -.
DR   MIM; 172420; gene.
DR   neXtProt; NX_P19174; -.
DR   OpenTargets; ENSG00000124181; -.
DR   PharmGKB; PA33392; -.
DR   eggNOG; KOG1264; Eukaryota.
DR   eggNOG; ENOG410XPXE; LUCA.
DR   GeneTree; ENSGT00730000110782; -.
DR   HOVERGEN; HBG053611; -.
DR   InParanoid; P19174; -.
DR   KO; K01116; -.
DR   OMA; TMDLPFL; -.
DR   OrthoDB; EOG091G07R3; -.
DR   PhylomeDB; P19174; -.
DR   TreeFam; TF313216; -.
DR   BRENDA; 3.1.4.11; 2681.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1251932; PLCG1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1489509; DAG and IP3 signaling.
DR   Reactome; R-HSA-167021; PLC-gamma1 signalling.
DR   Reactome; R-HSA-170968; Frs2-mediated activation.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-212718; EGFR interacts with phospholipase C-gamma.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-418890; Role of second messengers in netrin-1 signaling.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5654219; Phospholipase C-mediated cascade: FGFR1.
DR   Reactome; R-HSA-5654221; Phospholipase C-mediated cascade, FGFR2.
DR   Reactome; R-HSA-5654227; Phospholipase C-mediated cascade, FGFR3.
DR   Reactome; R-HSA-5654228; Phospholipase C-mediated cascade, FGFR4.
DR   Reactome; R-HSA-5655253; Signaling by FGFR2 in disease.
DR   Reactome; R-HSA-5655291; Signaling by FGFR4 in disease.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-8853338; Signaling by FGFR3 point mutants in cancer.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P19174; -.
DR   SIGNOR; P19174; -.
DR   ChiTaRS; PLCG1; human.
DR   EvolutionaryTrace; P19174; -.
DR   GeneWiki; PLCG1; -.
DR   GenomeRNAi; 5335; -.
DR   PRO; PR:P19174; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000124181; -.
DR   CleanEx; HS_PLCG1; -.
DR   ExpressionAtlas; P19174; baseline and differential.
DR   Genevisible; P19174; HS.
DR   GO; GO:0042995; C:cell projection; IDA:BHF-UCL.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0008180; C:COP9 signalosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0035254; F:glutamate receptor binding; IEA:Ensembl.
DR   GO; GO:0005168; F:neurotrophin TRKA receptor binding; IPI:UniProtKB.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0004629; F:phospholipase C activity; TAS:Reactome.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IEA:Ensembl.
DR   GO; GO:0005057; F:signal transducer activity, downstream of receptor; NAS:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IMP:BHF-UCL.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0009395; P:phospholipid catabolic process; IEA:InterPro.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:DFLAT.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IMP:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 2.30.29.30; -; 2.
DR   Gene3D; 2.60.40.150; -; 1.
DR   Gene3D; 3.20.20.190; -; 1.
DR   Gene3D; 3.30.505.10; -; 2.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR001192; PI-PLC_fam.
DR   InterPro; IPR016279; PLC-gamma.
DR   InterPro; IPR028380; PLC-gamma1.
DR   InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl.
DR   InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom.
DR   InterPro; IPR001711; PLipase_C_Pinositol-sp_Y.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR10336; PTHR10336; 1.
DR   PANTHER; PTHR10336:SF121; PTHR10336:SF121; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00388; PI-PLC-X; 1.
DR   Pfam; PF00387; PI-PLC-Y; 1.
DR   Pfam; PF00017; SH2; 2.
DR   Pfam; PF00018; SH3_1; 1.
DR   PIRSF; PIRSF000952; PLC-gamma; 1.
DR   PRINTS; PR00390; PHPHLIPASEC.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 3.
DR   SMART; SM00148; PLCXc; 1.
DR   SMART; SM00149; PLCYc; 1.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF51695; SSF51695; 2.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00018; EF_HAND_1; 1.
DR   PROSITE; PS50222; EF_HAND_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 2.
DR   PROSITE; PS50007; PIPLC_X_DOMAIN; 1.
DR   PROSITE; PS50008; PIPLC_Y_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Calcium;
KW   Cell projection; Complete proteome; Host-virus interaction; Hydrolase;
KW   Lipid degradation; Lipid metabolism; Metal-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; SH2 domain; SH3 domain;
KW   Transducer; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2   1290       1-phosphatidylinositol 4,5-bisphosphate
FT                                phosphodiesterase gamma-1.
FT                                /FTId=PRO_0000088498.
FT   DOMAIN       27    142       PH 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      152    187       EF-hand. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   DOMAIN      320    464       PI-PLC X-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00270}.
FT   DOMAIN      489    523       PH 2; first part. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      550    657       SH2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      668    756       SH2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      791    851       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      895    931       PH 2; second part. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      953   1070       PI-PLC Y-box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00271}.
FT   DOMAIN     1075   1177       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   CA_BIND     165    176       {ECO:0000255|PROSITE-ProRule:PRU00448}.
FT   ACT_SITE    335    335       {ECO:0000255|PROSITE-ProRule:PRU00270}.
FT   ACT_SITE    380    380       {ECO:0000255|PROSITE-ProRule:PRU00270}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     506    506       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q62077}.
FT   MOD_RES     771    771       Phosphotyrosine; by SYK.
FT                                {ECO:0000244|PubMed:15144186,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:20494825,
FT                                ECO:0000269|PubMed:8657103}.
FT   MOD_RES     775    775       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     783    783       Phosphotyrosine; by ITK, SYK and TXK.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:11564877,
FT                                ECO:0000269|PubMed:15215251,
FT                                ECO:0000269|PubMed:8657103}.
FT   MOD_RES     977    977       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q62077}.
FT   MOD_RES    1221   1221       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1227   1227       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1233   1233       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1248   1248       Phosphoserine.
FT                                {ECO:0000269|PubMed:1370476}.
FT   MOD_RES    1253   1253       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15144186,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1263   1263       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ    1215   1215       K -> KQ (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_038692.
FT   VARIANT     209    209       T -> N (in dbSNP:rs2229348).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_025213.
FT   VARIANT     279    279       S -> G (in dbSNP:rs2228246).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_022130.
FT   VARIANT     739    739       S -> T (in dbSNP:rs34203315).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_025214.
FT   VARIANT     813    813       I -> T (in dbSNP:rs753381).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_011908.
FT   STRAND      551    554       {ECO:0000244|PDB:4EY0}.
FT   STRAND      556    558       {ECO:0000244|PDB:4EY0}.
FT   HELIX       561    576       {ECO:0000244|PDB:4FBN}.
FT   STRAND      583    587       {ECO:0000244|PDB:4FBN}.
FT   STRAND      589    591       {ECO:0000244|PDB:4FBN}.
FT   STRAND      595    601       {ECO:0000244|PDB:4FBN}.
FT   STRAND      604    613       {ECO:0000244|PDB:4FBN}.
FT   HELIX       615    617       {ECO:0000244|PDB:4FBN}.
FT   STRAND      620    624       {ECO:0000244|PDB:4FBN}.
FT   STRAND      627    631       {ECO:0000244|PDB:4FBN}.
FT   HELIX       632    641       {ECO:0000244|PDB:4FBN}.
FT   STRAND      644    646       {ECO:0000244|PDB:4EY0}.
FT   STRAND      649    651       {ECO:0000244|PDB:4EY0}.
FT   HELIX       662    665       {ECO:0000244|PDB:4FBN}.
FT   STRAND      669    672       {ECO:0000244|PDB:4FBN}.
FT   HELIX       675    683       {ECO:0000244|PDB:4FBN}.
FT   STRAND      690    695       {ECO:0000244|PDB:4FBN}.
FT   STRAND      701    708       {ECO:0000244|PDB:4FBN}.
FT   STRAND      711    720       {ECO:0000244|PDB:4FBN}.
FT   STRAND      723    726       {ECO:0000244|PDB:4FBN}.
FT   STRAND      729    732       {ECO:0000244|PDB:4FBN}.
FT   HELIX       734    743       {ECO:0000244|PDB:4FBN}.
FT   HELIX       758    763       {ECO:0000244|PDB:4FBN}.
FT   STRAND      792    794       {ECO:0000244|PDB:1HSQ}.
FT   STRAND      805    809       {ECO:0000244|PDB:1HSQ}.
FT   STRAND      817    820       {ECO:0000244|PDB:2HSP}.
FT   TURN        825    827       {ECO:0000244|PDB:1HSQ}.
FT   STRAND      834    836       {ECO:0000244|PDB:1HSQ}.
FT   TURN        843    845       {ECO:0000244|PDB:1HSQ}.
SQ   SEQUENCE   1290 AA;  148532 MW;  AE05ABE2A18EDDAC CRC64;
     MAGAASPCAN GCGPGAPSDA EVLHLCRSLE VGTVMTLFYS KKSQRPERKT FQVKLETRQI
     TWSRGADKIE GAIDIREIKE IRPGKTSRDF DRYQEDPAFR PDQSHCFVIL YGMEFRLKTL
     SLQATSEDEV NMWIKGLTWL MEDTLQAPTP LQIERWLRKQ FYSVDRNRED RISAKDLKNM
     LSQVNYRVPN MRFLRERLTD LEQRSGDITY GQFAQLYRSL MYSAQKTMDL PFLEASTLRA
     GERPELCRVS LPEFQQFLLD YQGELWAVDR LQVQEFMLSF LRDPLREIEE PYFFLDEFVT
     FLFSKENSVW NSQLDAVCPD TMNNPLSHYW ISSSHNTYLT GDQFSSESSL EAYARCLRMG
     CRCIELDCWD GPDGMPVIYH GHTLTTKIKF SDVLHTIKEH AFVASEYPVI LSIEDHCSIA
     QQRNMAQYFK KVLGDTLLTK PVEISADGLP SPNQLKRKIL IKHKKLAEGS AYEEVPTSMM
     YSENDISNSI KNGILYLEDP VNHEWYPHYF VLTSSKIYYS EETSSDQGNE DEEEPKEVSS
     STELHSNEKW FHGKLGAGRD GRHIAERLLT EYCIETGAPD GSFLVRESET FVGDYTLSFW
     RNGKVQHCRI HSRQDAGTPK FFLTDNLVFD SLYDLITHYQ QVPLRCNEFE MRLSEPVPQT
     NAHESKEWYH ASLTRAQAEH MLMRVPRDGA FLVRKRNEPN SYAISFRAEG KIKHCRVQQE
     GQTVMLGNSE FDSLVDLISY YEKHPLYRKM KLRYPINEEA LEKIGTAEPD YGALYEGRNP
     GFYVEANPMP TFKCAVKALF DYKAQREDEL TFIKSAIIQN VEKQEGGWWR GDYGGKKQLW
     FPSNYVEEMV NPVALEPERE HLDENSPLGD LLRGVLDVPA CQIAIRPEGK NNRLFVFSIS
     MASVAHWSLD VAADSQEELQ DWVKKIREVA QTADARLTEG KIMERRKKIA LELSELVVYC
     RPVPFDEEKI GTERACYRDM SSFPETKAEK YVNKAKGKKF LQYNRLQLSR IYPKGQRLDS
     SNYDPLPMWI CGSQLVALNF QTPDKPMQMN QALFMTGRHC GYVLQPSTMR DEAFDPFDKS
     SLRGLEPCAI SIEVLGARHL PKNGRGIVCP FVEIEVAGAE YDSTKQKTEF VVDNGLNPVW
     PAKPFHFQIS NPEFAFLRFV VYEEDMFSDQ NFLAQATFPV KGLKTGYRAV PLKNNYSEDL
     ELASLLIKID IFPAKENGDL SPFSGTSLRE RGSDASGQLF HGRAREGSFE SRYQQPFEDF
     RISQEHLADH FDSRERRAPR RTRVNGDNRL
//
